Jasper Therapeutics
JSPR
81 hedge funds and large institutions have $275M invested in Jasper Therapeutics in 2024 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 23 increasing their positions, 20 reducing their positions, and 12 closing their positions.
141% more call options, than puts
Call options by funds: $3.39M | Put options by funds: $1.4M
100% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 12
17% more funds holding
Funds holding: 69 → 81 (+12)
15% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 20
0.67% more ownership
Funds ownership: 96.52% → 97.19% (+0.67%)
17% less capital invested
Capital invested by funds: $330M → $275M (-$55M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
+$9.62M |
| 2 |
IHAM
Integral Health Asset Management
New York
|
+$6.97M |
| 3 |
Morgan Stanley
New York
|
+$5.1M |
| 4 |
ABG
Ally Bridge Group
New York
|
+$3.6M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$2.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$17.8M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
-$6.53M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$5.28M |
| 4 |
SC
Stempoint Capital
New York
|
-$3.26M |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$2.49M |
JSPR Hedge Fund Activity: Q3 2024 in Review
81 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q3 2024, worth a combined $275M — down 17% from $330M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new JSPR positions and 12 closed out — a net gain of 12 holders — while 23 added to existing stakes and 20 trimmed.
The largest buyer was Braidwell, opening a new position worth an estimated $9.62M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $17.8M sold.
- 81 institutional investors held Jasper Therapeutics (JSPR) as of Q3 2024, up from 69 in Q2 2024.
- Funds reported $275M of Jasper Therapeutics stock for Q3 2024, down 17% quarter-over-quarter.
- 24 funds opened new Jasper Therapeutics positions in Q3 2024 and 12 closed out, a net change of +12 holders.
- The largest Jasper Therapeutics buyer in Q3 2024 was Braidwell, an estimated $9.62M added.
- The largest Jasper Therapeutics seller in Q3 2024 was Avidity Partners Management, an estimated $17.8M sold.
Based on aggregated 13F filings for Q3 2024.